Suchergebnisse - "Kessels, Lonneke W"

PubPharm (15)

1

Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer

enthalten in: JAMA network open | 2021

von van Nassau, S. | Bond, M. | Scheerman, I. | +84

2

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial

enthalten in: Breast cancer research and treatment | 2021

von Lugtenberg, R. | de Groot, S. | Kaptein, A. | +19

3

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

enthalten in: Breast cancer research and treatment | 2020

von Lugtenberg, R. | de Groot, S. | Kaptein, A. | +18

4

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

enthalten in: Breast cancer research and treatment | 2020

von Lugtenberg, R. | de Groot, S. | Kaptein, A. | +18

5

Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013–14) trial

enthalten in: Breast cancer research and treatment | 2020

von Lugtenberg, R. | de Groot, S. | Kaptein, A. | +18

6

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

enthalten in: Nature communications | 2020

von de Groot, S. | Lugtenberg, R. | Cohen, D. | +34

CommentIn: Nat Commun. 2020 Aug 26;11(1):4274. - PMID 32848145

7

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer : 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

enthalten in: Breast cancer research : BCR | 2019

von de Groot, S. | Pijl, H. | Charehbili, A. | +17

8

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

enthalten in: Breast cancer research | 2019

von de Groot, S. | Pijl, H. | Charehbili, A. | +16

9

Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

enthalten in: Breast cancer research | 2019

von de Groot, S. | Pijl, H. | Charehbili, A. | +16

10

Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients : results from the NEOZOTAC trial (BOOG 2010-01)

enthalten in: Breast cancer research : BCR | 2016

von de Groot, S. | Charehbili, A. | van Laarhoven, H. | +16